HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Published:2021-09 Issue: Volume:21 Page:S373-S374
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Ansell Stephen,Bröckelmann Paul,von Keudell Gottfried,Lee Hun Ju,Santoro Armando,Zinzani Pier Luigi,Collins Graham,Cohen Jonathon,De Boer Jan Paul,Kuruvilla John,Savage Kerry,Trněný Marek,Provencio Mariano,Jaeger Ulrich,Willenbacher Wolfgang,Swanink Rene,Shipp Margaret,Engert Andreas,Armand Philippe

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Very late relapse in Hodgkin lymphoma: Characterizing an understudied population;Clinical Lymphoma Myeloma and Leukemia;2023-11

2. Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma;British Journal of Haematology;2023-10-31

3. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade;Blood;2023-10-19

4. Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review;Biomedicines;2023-06-15

5. Long-term outcomes for patients with Hodgkin lymphoma at increased risk of progression or relapse;Leukemia & Lymphoma;2022-10-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP